scholarly journals High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR

2013 ◽  
Vol 11 (1) ◽  
pp. 90 ◽  
Author(s):  
Fang Wang ◽  
Sha Fu ◽  
Qiong Shao ◽  
Yan-Bin Zhou ◽  
Xiao Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Copy Number ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Inhibitor Treatment

The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrospective analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e19030-e19030
Author(s):  
Giuseppe Bronte ◽  
Tindara Franchina ◽  
Massimiliano Alù ◽  
Giovanni Sortino ◽  
Claudia Celesia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Kinase Inhibitor ◽  
Small Cell ◽  
Second Line ◽  
Wild Type ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

2018 ◽  
Vol Volume 10 ◽  
pp. 5537-5544 ◽  
Author(s):  
Stefan Diem ◽  
Mirjam Fässler ◽  
Omar Hasan Ali ◽  
Marco Siano ◽  
Rebekka Niederer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Risk Score ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Inhibitor Treatment
Sign in / Sign up

Export Citation Format

Share Document